Adinazolam sustained release formulation in the treatment of generalized anxiety disorder

Abstract

A 6 week open label trial, followed by a 1–6 week taper/discontinuation phase, was conducted to assess the safety and efficacy of the sustained release formulation of adinazolam in 7 outpatients with generalized anxiety disorder. Adinazolam-SR was well tolerated and produced a rapid and significant improvement in the severity of anxiety, phobias, disability, and depressive symptoms. The duration of therapeutic action of this formulation of adinazolam was 12.2 ± 2.6 hours. Relapse was common, using the study's speed of withdrawal. However, rebound occurred in only one patient and withdrawal symptoms were few.